Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 10 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
ImmunityBio Inc. has 13 pending office actions within the Biotechnology & Pharmaceuticals sector. The portfolio is handled by 13 distinct examiners across 9 distinct art units. KONOPELSKI SNAVEL, SARA ELIZABETH is the busiest examiner with 1 busiest examiner pending action. The 9 distinct art units indicate the technical breadth within the company's biotechnology interests.
With 13 distinct examiners for the 13 pending office actions, the workload is perfectly distributed. This means that every pending office action is being reviewed by a different individual, requiring the company to navigate 13 different examiner styles. The 1 busiest examiner pending action assigned to KONOPELSKI SNAVEL, SARA ELIZABETH represents a small portion of the 13 pending office actions. Practitioners should focus on the specific preferences of each examiner to ensure successful outcomes.
The 9 distinct art units suggest that the portfolio touches on several specialized groups within the USPTO. Managing 13 pending office actions across these units requires an understanding of the specific technical standards applied by each group. Because the 13 distinct examiners are spread across 9 distinct art units, there is significant variety in the technical scrutiny applied to the applications. This structure requires a prosecution strategy that accounts for both individual examiner preferences and art unit trends.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (21%) |
| §103 only | 2 (14%) |
| §112 only | 2 (14%) |
| Double-patenting + other | 2 (14%) |
| Multi-statute (no §101) | 5 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| SANG, HONG | 1 | 55.0% | +62.4% |
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
| DUFFY, BRADLEY | 1 | 54.5% | +45.8% |
| ZAIDI, SYED A | 1 | 81.9% | +12.2% |
| WILLIAMS, KEITH RICHARD | 1 | 50.0% | +0.0% |
| WANG, RUIXUE | 1 | 57.4% | +17.8% |
| PETRASH, HILARY ANN | 1 | 64.5% | +51.7% |
| CARTER, SANDRA DILLAHUNT | 1 | 56.2% | +29.0% |
| BENAVIDES, JENNIFER ANN | 1 | 51.2% | +47.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 23d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 22d overdue |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 16d |
| 19399287 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | SANG, HONG | — |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | STAVROU, CONSTANTINA E | — |
| 18882219 | Nant COVID Vaccine Cross Reactivity | WANG, RUIXUE | — |
| 18509777 | Compositions And Methods Of MAIT Cell Activation | PETRASH, HILARY ANN | — |
| 18278797 | Highly Potent M-CENK Cells And Methods | BENAVIDES, JENNIFER ANN | — |
| 16576415 | SAMPLE DESTRUCTION VALIDATION SYSTEM AND METHODS | FONTAINHAS, AURORA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 12d |
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 23d |
| 19407885 | Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 19399287 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | SANG, HONG | — |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | STAVROU, CONSTANTINA E | — |
| 18882219 | Nant COVID Vaccine Cross Reactivity | WANG, RUIXUE | — |
| 18509777 | Compositions And Methods Of MAIT Cell Activation | PETRASH, HILARY ANN | — |
| 18497169 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | CARTER, SANDRA DILLAHUNT | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1658 | 1 |
| 1646 | 1 |
| 1632 | 1 |
| 1643 | 1 |
| 2432 | 1 |
| 1663 | 1 |
| 1687 | 1 |
| 1685 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19407885 | Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Final Rejection | — | Pending | Dec 03, 2025 |
| 19399287 | NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives Thereof | SANG, HONG | 1646 | §102§112 | Final Rejection | — | Pending | Nov 24, 2025 |
| 19357552 | DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLS | STAVROU, CONSTANTINA E | 1632 | §102§103 | Final Rejection | — | Pending | Oct 14, 2025 |
| 19277274 | COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTS | DUFFY, BRADLEY | 1643 | §103 | Final Rejection | 12d | Pending | Jul 22, 2025 |
| 19211886 | CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODS | ZAIDI, SYED A | 2432 | §103 | Final Rejection | 23d | Pending | May 19, 2025 |
| 18897262 | Methods And Systems For Producing A Protein Of Interest In A Plant | WILLIAMS, KEITH RICHARD | 1663 | §112 | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18882219 | Nant COVID Vaccine Cross Reactivity | WANG, RUIXUE | — | §102§103§112Other | Non-Final OA | — | Pending | Sep 11, 2024 |
| 18509777 | Compositions And Methods Of MAIT Cell Activation | PETRASH, HILARY ANN | — | §102§103§112 | Non-Final OA | — | Pending | Nov 15, 2023 |
| 18497169 | MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF | CARTER, SANDRA DILLAHUNT | — | §112 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18278797 | Highly Potent M-CENK Cells And Methods | BENAVIDES, JENNIFER ANN | 1675 | §103§112 | Non-Final OA | — | Pending | Aug 24, 2023 |
| 18225098 | COMPUTING AFFINITY FOR PROTEIN-PROTEIN INTERACTION | ANDERSON-FEARS, KEENAN NEIL | 1687 | §101§103 | Final Rejection | 22d overdue | Pending | Jul 21, 2023 |
| 17767615 | Detecting Homologous Recombination Deficiencies (HRD) in Clinical Samples | LIN, JERRY | 1685 | §101§103 | Final Rejection | 16d | Pending | Apr 08, 2022 |
| 17630075 | ANTIBODY PRE-LOADED CD16+NK-92 CELLS AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS | LU, CHENG | 1642 | §103§112DP | Non-Final OA | — | Pending | Jan 25, 2022 |
| 16576415 | SAMPLE DESTRUCTION VALIDATION SYSTEM AND METHODS | FONTAINHAS, AURORA M | 1675 | §101§112 | Non-Final OA | — | Pending | Sep 19, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial